COPD Management with Inhaler Therapy

Initial Assessment and Classification

The American Thoracic Society recommends classifying COPD patients according to symptom burden and exacerbation history to guide appropriate inhaler therapy 2
Key assessment tools include the COPD Assessment Test (CAT) score or modified Medical Research Council (mMRC) dyspnea scale for symptom assessment, as recommended by the American College of Chest Physicians 2
Exacerbation history (frequency and severity) is crucial for determining appropriate inhaler therapy, according to the American Journal of Respiratory and Critical Care Medicine 3, 2

For patients with mild COPD, the American College of Chest Physicians recommends short-acting bronchodilators (SABA or SAMA) as needed for symptom relief 4, 2
The American College of Chest Physicians suggests considering long-acting bronchodilator maintenance therapy even in patients with mild symptoms 1
For patients with moderate COPD, the American Thoracic Society recommends long-acting bronchodilator therapy over short-acting bronchodilators 3, 1
LAMA/LABA combination is superior to either LAMA or LABA monotherapy for symptom relief in moderate to severe COPD, as stated by the American Journal of Respiratory and Critical Care Medicine 3, 1

Short-acting β2-agonists (SABAs) produce bronchodilation within minutes, reaching peak effect at 15-30 minutes with duration of 4-5 hours, according to the European Respiratory Journal 5, 6
Long-acting muscarinic antagonists (LAMAs) are preferred over long-acting β2-agonists (LABAs) for exacerbation prevention, as recommended by the American Journal of Respiratory and Critical Care Medicine 3
The American College of Chest Physicians recommends using LAMA/LABA combinations for symptom relief in patients with moderate to severe COPD 3, 1

LAMA/LABA combinations show superior results compared to single bronchodilators for symptom relief in COPD patients, according to the American Journal of Respiratory and Critical Care Medicine 3
For patients who develop additional exacerbations on LABA/LAMA therapy, escalation to LAMA/LABA/ICS triple therapy is recommended by the American Journal of Respiratory and Critical Care Medicine 3, 1

Long-term monotherapy with ICS is not recommended in COPD, as stated by the American Journal of Respiratory and Critical Care Medicine 3
ICS should be used in combination with long-acting bronchodilators, particularly in patients with a history of exacerbations, according to the American Journal of Respiratory and Critical Care Medicine 7, 3

The inhaled route of drug delivery results in fewer adverse effects compared to oral administration, as reported by the European Respiratory Journal 5, 6
Proper inhaler technique should be taught at the first prescription and checked periodically, as recommended by the European Respiratory Journal 5, 6